Don’t Consider Sotagliflozin a Diabetes Med

New Rx sotagliflozin (Inpefa) will join dapagliflozin (Farxiga), empagliflozin (Jardiance), and other SGLT2 inhibitors.

But sotagliflozin is the only SGLT2 inhibitor NOT yet approved for treating type 2 diabetes.

It’s currently only approved to reduce the risk of heart failure urgent care visits and hospitalizations and cardiovascular certain adults with OR without diabetes.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote